As a result of the t(9; 22)(q34; q11.2), the chimeric BCR-ABL1 fusion protein was a constitutively active tyrosine kinase that leads to leukemogenesis, the introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in CML.25 The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.